158 related articles for article (PubMed ID: 19138962)
21. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
Flotho C; Claus R; Batz C; Schneider M; Sandrock I; Ihde S; Plass C; Niemeyer CM; Lübbert M
Leukemia; 2009 Jun; 23(6):1019-28. PubMed ID: 19194470
[TBL] [Abstract][Full Text] [Related]
22. Promises and challenges of anticancer drugs that target the epigenome.
Verbrugge I; Johnstone RW; Bots M
Epigenomics; 2011 Oct; 3(5):547-65. PubMed ID: 22126246
[TBL] [Abstract][Full Text] [Related]
23. Novel cancer drugs based on epigenetics, miRNAs and their interactions.
Roukos DH
Epigenomics; 2011 Dec; 3(6):675-8. PubMed ID: 22126285
[No Abstract] [Full Text] [Related]
24. Clinical and biological effects of demethylating agents on solid tumours - A systematic review.
Linnekamp JF; Butter R; Spijker R; Medema JP; van Laarhoven HWM
Cancer Treat Rev; 2017 Mar; 54():10-23. PubMed ID: 28189913
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic DNA methylation in radiation biology: on the field or on the sidelines?
Zielske SP
J Cell Biochem; 2015 Feb; 116(2):212-7. PubMed ID: 25186310
[TBL] [Abstract][Full Text] [Related]
26. DNA methylation and cancer.
Momparler RL; Bovenzi V
J Cell Physiol; 2000 May; 183(2):145-54. PubMed ID: 10737890
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes.
Klimek VM; Dolezal EK; Tees MT; Devlin SM; Stein K; Romero A; Nimer SD
Leuk Res; 2012 Sep; 36(9):1093-7. PubMed ID: 22608310
[TBL] [Abstract][Full Text] [Related]
28. The role of epigenetics in cancer. DNA Methylation, Imprinting and the Epigenetics of Cancer--an American Association for Cancer Research Special Conference. Las Croabas, Puerto Rico, 12-16 1997 December.
Lengauer C; Issa JP
Mol Med Today; 1998 Mar; 4(3):102-3. PubMed ID: 9575489
[No Abstract] [Full Text] [Related]
29. Epigenetic therapy with decitabine for myelodysplasia and leukemia.
Wijermans P; Lübert M
Future Oncol; 2005 Oct; 1(5):585-91. PubMed ID: 16556035
[TBL] [Abstract][Full Text] [Related]
30. Zebularine: a new drug for epigenetic therapy.
Yoo CB; Cheng JC; Jones PA
Biochem Soc Trans; 2004 Dec; 32(Pt 6):910-2. PubMed ID: 15506921
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine.
Lemaire M; Momparler LF; Raynal NJ; Bernstein ML; Momparler RL
Cancer Chemother Pharmacol; 2009 Feb; 63(3):411-6. PubMed ID: 18398609
[TBL] [Abstract][Full Text] [Related]
32. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines.
Stresemann C; Brueckner B; Musch T; Stopper H; Lyko F
Cancer Res; 2006 Mar; 66(5):2794-800. PubMed ID: 16510601
[TBL] [Abstract][Full Text] [Related]
33. Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers.
Valinluck V; Sowers LC
Cancer Res; 2007 Jun; 67(12):5583-6. PubMed ID: 17575120
[TBL] [Abstract][Full Text] [Related]
34. The epigenetics of cancer in children.
Frühwald MC; Witt O
Klin Padiatr; 2008; 220(6):333-41. PubMed ID: 18949667
[TBL] [Abstract][Full Text] [Related]
35. Current status of epigenetic treatment in myelodysplastic syndromes.
Kuendgen A; Lübbert M
Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
[TBL] [Abstract][Full Text] [Related]
36. DNA demethylation protects from cleavable complex stabilization and DNA strand breakage induced by the topoisomerase type I inhibitor camptothecin.
Orta ML; Mateos S; Cortés F
Mutagenesis; 2009 May; 24(3):237-44. PubMed ID: 19201781
[TBL] [Abstract][Full Text] [Related]
37. The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.
Abou Zahr A; Saad Aldin E; Barbarotta L; Podoltsev N; Zeidan AM
Expert Rev Anticancer Ther; 2015; 15(9):1019-36. PubMed ID: 26292903
[TBL] [Abstract][Full Text] [Related]
38. Ectopic expression of activation-induced cytidine deaminase caused by epigenetics modification.
Tatemichi M; Hata H; Nakadate T
Oncol Rep; 2011 Jan; 25(1):153-8. PubMed ID: 21109971
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer.
McCabe MT; Low JA; Daignault S; Imperiale MJ; Wojno KJ; Day ML
Cancer Res; 2006 Jan; 66(1):385-92. PubMed ID: 16397253
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic regulation of microRNA expression in cancer.
Choudhry H; Catto JW
Methods Mol Biol; 2011; 676():165-84. PubMed ID: 20931397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
